mogamulizumab   Click here for help

GtoPdb Ligand ID: 6477

Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
Approved drug Immunopharmacology Ligand
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class: Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (PMDA (Japan, 2012), EMA & FDA (2018))
Approved drug? Yes. PMDA (Japan) (2012)  |  EMA (2018)  |  FDA (2018)
International Nonproprietary Names Click here for help
INN number INN
9374 mogamulizumab
Synonyms Click here for help
KW-0761 | mogamulizumab-kpkc | Poteligeo®
Database Links Click here for help
Specialist databases
GPCRdb Ligand mogamulizumab
IMGT/mAb-DB 366
Other databases
GtoPdb PubChem SID 178103091
PubChem SID 178103091
Search PubMed clinical trials mogamulizumab
Search PubMed titles mogamulizumab
Search PubMed titles/abstracts mogamulizumab
Wikipedia Mogamulizumab